Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immunomedics reports clinical findings for cancer therapeutic

Jan. 28, 2000

No Comments

Biomira initiates next stage of phase II testing of BLP25/liposomal IL-2

Jan. 26, 2000

No Comments

Neurocrine Biosciences updates clinical progress with IL-4 fusion toxin

Jan. 21, 2000

No Comments

Avax Technologies' O-Vax IND accepted

Jan. 19, 2000

No Comments

Oxford BioMedica acquires novel antibody technology

Jan. 17, 2000

No Comments

AltaRex in-licenses antibody from NIH for AIT platform

Jan. 14, 2000

No Comments

Ligand sells Marathon assets to CoPharma

Jan. 14, 2000

No Comments

Japanese marketing approval no longer sought for Mochida's TNF

Jan. 12, 2000

No Comments

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Jan. 11, 2000

No Comments

New developments announced for AltaRex's ovarian cancer therapy

Jan. 6, 2000

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Immuno-oncology
RSS

Immunomedics reports clinical findings for cancer therapeutic

Biomira initiates next stage of phase II testing of BLP25/liposomal IL-2

Neurocrine Biosciences updates clinical progress with IL-4 fusion toxin

Avax Technologies' O-Vax IND accepted

Oxford BioMedica acquires novel antibody technology

AltaRex in-licenses antibody from NIH for AIT platform

Ligand sells Marathon assets to CoPharma

Japanese marketing approval no longer sought for Mochida's TNF

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

New developments announced for AltaRex's ovarian cancer therapy

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

AI drives financings, approvals for APAC med-tech in 2024

Immuno-oncology RSS

Immuno-oncology
RSS